Sourcing, Safety & Regulation
The regulation landscape is messy
Only a small number of peptides have FDA approval (insulin, semaglutide, tirzepatide, liraglutide, tesamorelin, some others). Most of the "longevity peptides" people discuss sit in one of three grey zones: compounded by a licensed pharmacy (legal but restricted), research-chemical (not for human use, but sold), or unapproved import.
FDA has been tightening
In 2023–2024 the FDA moved BPC-157, ipamorelin, CJC-1295 (no DAC), and several others from the compounding bulks list — making them harder for US compounding pharmacies to legally prepare. The market didn't disappear; it just moved further underground.
Select every red flag in a peptide source:
Which of these should make you walk away?
The interaction problem nobody mentions
Peptides interact with pharmaceuticals, and nobody is tracking it for you. A GLP-1 slows gastric emptying — so the absorption of every pill you take changes. Hormone-axis peptides alter glucose and cortisol — changing insulin needs and steroid interactions. Always run your full stack through an interaction check before adding a peptide.
Stack checks save emergencies
Published case reports describe DKA, pancreatitis, and serotonin syndrome in peptide-plus-pharmaceutical combinations that weren't flagged. The pattern: multiple specialists, nobody sees the full list. Keep one list. Check it every time something new is added.
Key Takeaway
Peptide pharmacology is real and interesting. Peptide sourcing is largely unregulated and uneven. Peptide interactions are under-recognised. The minimum viable safety practice: prescription-route where available, third-party purity verified for the rest, full stack reviewed with every addition.
References
- FDA 503A bulk compounding restrictions on peptides